5 • 604 Ratings
🗓️ 15 April 2025
⏱️ 33 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
0:00.0 | Well, hello, hello, guys. You're listening to Beauty Bites with Dr. K, Secrets of a Plastic Surgeon. |
0:17.9 | And today's podcast is going to blow your mind. We're going to talk |
0:22.2 | the nitty gritty about all things legal and lawful and what to do in your practice, what not to do |
0:28.4 | in your practice. We're introducing Sarah Schickman. This is part two. We did a really great part one |
0:33.8 | podcast. I encourage you to go back and find it. But there's so much new technology and |
0:38.6 | the molecular biology of aging is happening before our eyes and people are doing crazy stuff out |
0:43.8 | there, Sarah. It's the Wild West. Welcome to the podcast and tell us about your legal background a little bit. |
0:49.8 | Sure. My name is Sarah Shickman. I've been a lawyer since 2007. I worked at some big firms and I started a med spa that grew to 12 locations. And then in 2019, I started this law firm called Lin Gia Law. And we really focus on the aesthetic industry and we represent over 1,500 practices in this space with |
1:12.2 | everything from helping people start to helping people sell to helping people resolve really |
1:17.8 | difficult patient issues or staff issues or, you know, doing products that they're not |
1:25.5 | supposed to be doing issues. So we specialize in being the fixer to our |
1:30.1 | clients and also the guide to help people not make mistakes in the first place. I love that. |
1:36.9 | You are a boss girl. It's 16 years or more of law experience and then running basically a |
1:43.4 | multi-million dollar venture with this big spot |
1:46.2 | chain as well as the e-commerce that they're doing. So I think you must have seen lots of regulatory |
1:51.3 | issues. What right now are some big red flags in the medical spa industry? I think one emerging |
1:59.4 | issue is GOP ones and their change from being on the FDA shortage |
2:05.7 | list to not being on the FDA shortage list. |
2:08.8 | So previously, semi-glutide and terseptide were on the FDA shortage list, which meant |
2:16.2 | that compounding pharmacies could essentially make a copy of |
2:19.8 | them and sell them to medsbas. So even though they were these brand-name drugs like Ozimpec and |
2:27.7 | Monjaro, because they were on the shortage list, compounding pharmacies could make the generic |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Kay Durairaj, MD, FACS @beautybydrkay, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Kay Durairaj, MD, FACS @beautybydrkay and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.